Genomic Insights for Personalized Care: Motivating At-Risk Individuals Toward Evidence-Based Health Practices

3

4 Tony Chen^{1,*}, Giang Pham², Louis Fox², Nina Adler^{3,4}, Xiaoyu Wang^{5,6}, Jingning Zhang⁷,

- 5 Jinyoung Byun⁸, Younghun Han⁸, Gretchen R.B. Saunders⁹, Dajiang Liu¹⁰, Michael J.
- 6 Bray^{11,12}, Alex T. Ramsey², James McKay¹³, Laura Bierut², Christopher I. Amos^{8,14},

7 Rayjean J. Hung⁴, Xihong Lin^{1,15}, Haoyu Zhang^{5,†,*}, Li-Shiun Chen^{2,†,*}

- 8
- ⁹ ¹ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA
- ² Department of Psychiatry, Washington University School of Medicine, St. Louis, USA
- ³ Department of Anthropology, University of Toronto, Mississauga, ON, Canada
- ⁴ Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research
- 13 Institute, Sinai Health, and University of Toronto, Toronto, Canada
- ⁵ Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda,
 MD, USA
- ⁶ Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer
 Research, Leidos Biomedical Research Inc, Rockville, MD, USA
- ⁷ Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health,
 Baltimore, USA.
- ⁸ Department of Medicine, Section of Epidemiology and Population Science, Institute for
- 21 Clinical and Translational Research, Houston, TX, USA
- ⁹ Department of Psychology, University of Minnesota, Minneapolis, MN, USA
- ¹⁰ Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA,
 USA
- ¹¹ Department of Genetic Counseling, Bay Path University, Longmeadow, MA, USA
- 26 ¹² ThinkGenetics, Inc, USA
- ¹³ International Agency for Research on Cancer, World Health Organization, Lyon,
 France
- ¹⁴ Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston,
- 30 TX, USA
- 31 ¹⁵ Department of Statistics, Harvard University, Cambridge, USA
- 32
- *Correspondence to: Tony Chen (<u>tonychen@g.harvard.edu</u>), Haoyu Zhang
 (haoyu.zhang2@nih.gov) and Li-Shiun Chen (li-shiun@wustl.edu).
- ³⁵ †These authors jointly supervised this work: Haoyu Zhang and Li-Shiun Chen.

36 Abstract

Background: Lung cancer and tobacco use pose significant global health challenges,
necessitating a comprehensive translational roadmap for improved prevention
strategies. Polygenic risk scores (PRSs) are powerful tools for patient risk stratification
but have not yet been widely used in primary care for lung cancer, particularly in diverse
patient populations.

42

Methods: We propose the GREAT care paradigm, which employs PRSs to stratify disease risk and personalize interventions. We developed PRSs using large-scale multiancestry genome-wide association studies and standardized PRS distributions across all ancestries. We applied our PRSs to 796 individuals from the GISC Trial, 350,154 from UK Biobank (UKBB), and 210,826 from All of Us Research Program (AoU), totaling 561,776 individuals of diverse ancestry.

49

Results: Significant odds ratios (ORs) for lung cancer and difficulty quitting smoking
were observed in both UKBB and AoU. For lung cancer, the ORs for individuals in the
highest risk group (top 20% versus bottom 20%) were 1.85 (95% CI: 1.58 – 2.18) in
UKBB and 2.39 (95% CI: 1.93 – 2.97) in AoU. For difficulty quitting smoking, the ORs
(top 33% versus bottom 33%) were 1.36 (95% CI: 1.32 – 1.41) in UKBB and 1.32 (95%
CI: 1.28 – 1.36) in AoU.

56

57 **Conclusion**: Our PRS-based intervention model leverages large-scale genetic data for 58 robust risk assessment across populations. This model will be evaluated in two cluster-59 randomized clinical trials aimed at motivating health behavior changes in high-risk 60 patients of diverse ancestry. This pioneering approach integrates genomic insights into 61 primary care, promising improved outcomes in cancer prevention and tobacco treatment. 62

Keywords: Lung Cancer, Polygenic risk scores, Cancer prevention, Personalized
 interventions, Translational roadmap, Health behavior change

65 Introduction

The worldwide burden of lung cancer and tobacco smoking presents major challenges 66 67 to global health¹. Evidence-based practices to reduce their risk such as cancer screening and tobacco treatment (e.g. smoking cessation medication) have long existed 68 69 but are infrequently used in most primary care practices. Communication of the 70 precision risk of lung cancer and precision benefit of smoking cessation is a promising 71 but untested strategy to promote health behavior changes to reduce cancer risk. To 72 address this gap, polygenic risk scores (PRSs) emerge as a valuable approach to 73 assess disease susceptibility among populations and pinpoint individuals at higher risk²⁻ 74 ⁴. PRSs can be derived from large-scale genome-wide association studies (GWAS) to 75 estimate individual disease risk and have shown promise in predicting health outcomes and promoting preventive healthcare^{5–9}. Despite their potential, PRSs' implementation in 76 77 primary care is limited, especially in diverse populations. Implementing a PRS-based 78 precision intervention is crucial in order to address the multifaceted needs of different 79 communities and individuals¹⁰. Harnessing PRSs effectively can make significant progress in mitigating lung cancer's public health impact. 80

81

Ongoing studies like eMERGE¹¹, GenoVA¹², and WISDOM¹³ are leading the 82 implementation of PRS into genetic risk reports (Table 1). They aim to personalize 83 84 medical reports and understand the impact of PRS on screening, diagnostic procedures, and patient behavior. Notably, a gap persists as these initiatives have not yet formulated 85 86 a PRS specifically for lung cancer. A likely reason is that the global burden of lung cancer is primarily driven by tobacco smoking rather than genetics^{14,15}. However, 87 88 accounting for the genetic basis of lung cancer may provide patients and clinicians with additional actionable information. The unique value proposition of a lung cancer-specific 89 90 PRS lies in leveraging established and clear guideline-based prevention strategies, including smoking cessation treatment and lung cancer screening¹⁶. By incorporating 91 92 PRSs for lung cancer and difficulty quitting smoking without treatment, there is an 93 opportunity to revitalize and enhance these often-under-utilized prevention practices. 94

95 We introduce the Genomic Informed Care for Motivating High Risk Individuals Eligible 96 for Evidence-based Prevention (GREAT) framework as a novel approach to incorporate 97 PRS-enabled interventions in clinical settings (Figure 1). The core of GREAT is the use of PRSs that offer precise risk estimates for lung cancer and difficulty quitting smoking. 98 99 By providing patients with personalized risk information, we aim to activate behavior 100 change mechanisms that promote preventive actions. The primary targets of this 101 intervention are high-risk individuals eligible for evidence-based prevention practices, 102 such as lung cancer screening and smoking cessation. By integrating precision risk 103 information with the benefits of timely interventions, GREAT empowers patients to make 104 informed decisions about their health and motivates them to take proactive steps 105 towards prevention. The personalized information may increase the patient uptake of 106 evidence-based treatment by activating potential mechanisms such as treatment. 107 Guided by enhanced outcome expectancy and self-efficacy based on the Capability-Opportunity-Motivation-Behavior (COM-B) model and Theoretical Domains Framework 108 109 (TDF)^{17–19}. Ultimately, our objective is not only to motivate, but to significantly reduce 110 lung cancer morbidity and mortality through this innovative care paradigm.

111

Effectively translating PRSs into clinical practice requires a comprehensive and 112 113 pragmatic translational roadmap for equitable and effective implementation (Figure 1). 114 First, to address ancestry diversity, we take a two-step approach of (1) constructing 115 PRS based on large-scale multi-ancestry GWAS, and (2) standardizing PRS distributions across the continuum of genetic ancestry to ensure accurate risk 116 stratification based on PRS distributions for all patients²⁰. Second, to document 117 118 accuracy and transportability of the PRSs to diverse populations, we perform large-119 scale validation using diverse data from the Genetic Informed Smoking Cessation (GISC) trial²¹, UK Biobank (UKBB)²², and All of Us Research program (AoU)²³. Third, 120 121 we translate risk into actionable categories by setting appropriate thresholds for the 122 PRS. The alignment of these thresholds with clinical significance involves many considerations for meaningful risk stratification. Fourth, we propose clear and patient-123 124 friendly communication strategies, including visual aids and educational materials, to facilitate understanding and meaningful interactions between patients and healthcare 125

126 providers. Effectively communicating both the risk and precision of the PRS results is 127 challenging but essential to empower patients to make informed decisions about their 128 health. Moreover, it is crucial to consider patient perceived risk, perceived benefit, and personal relevance when discussing PRS results with patients. Patients' understanding 129 130 and interpretation of PRS may vary, leading to differing levels of engagement in preventive actions. Hence, comprehensive patient education programs can enhance 131 132 awareness and knowledge about PRS, its implications, and available preventive 133 measures.

134

In this paper, we introduce the design for two cluster randomized clinical trials (RCT): (1) 135 136 PRECISE, which evaluates the effectiveness of a multilevel intervention, *RiskProfile*, on increasing lung cancer screening and tobacco treatment utilization in primary care 137 (NIDA Grant 5R01CA268030-02); and (2) MOTIVATE, which evaluates the effect of 138 PrecisionTx, a multilevel intervention to promote precision tobacco treatment in primary 139 care (NIDA Grant 5R01DA056050-02). Through the innovative use of PRS, our aim is to 140 141 motivate lung cancer screening and tobacco treatment among high-risk patients. We 142 present a new care paradigm (Figure 1) and outline a translational roadmap (Figure 2) 143 that discusses potential barriers and solutions for implementation. By incorporating 144 personalized risk assessments, such PRS-enabled interventions have the potential to 145 significantly improve lung cancer prevention strategies and patient outcomes.

146

147 Materials and Methods

148 <u>1000 Genomes Project Phase 3 reference data and principal components analysis</u>

We use the 1000 Genomes Project Phase 3 (1000G)^{24,25} as a reference for genetic ancestry inference, as it is publicly accessible and includes genotype data from diverse populations. The 1000G dataset includes 3,202 individuals, with 633 Europeans (EUR), 893 Africans (AFR), 585 East Asians (EAS), 601 South Asians (SAS), and 490 Admixed Americans (AMR). We conducted principal components analysis (PCA) plink 2.0²⁶ on all 3,202 samples, using 55,248 SNPs that are shared among the recommended SNPs set by gnomAD²⁷, 1000G reference data, UKBB and GISC validation data, and the

156 23andMe genotyping array used for the trial (Figure 3, Supplementary Figure 1,
 157 Supplementary Table 4).

158

We ran a random forest classifier to map each individual in 1000G to their respective populations using the first 5 PC scores. We then projected our validation data to this PC space and applied the same random forest classifier to produce "genetically-inferred" ancestry labels. Individuals with a predicted probability less than 90% for any of the five ancestries were labeled as "Other." While our proposed framework removes the need for labels in the clinic, we use them here for illustrative purposes in validation.

165

166 Validation in GISC, UK Biobank, and All of Us

We validated our PRS approaches in three datasets: Genetically Informed Smoking Cessation Trial (GISC)²¹, UK Biobank (UKBB)²², and All of Us Research Program (AoU)²³ Here we present are brief background of the three studies. More details of the study background are provided in the **Supplementary Note**, and sample characteristics regarding sex, age, and outcomes information in UKBB and AoU are provided in **Supplementary Table 1.**

173

<u>GISC Trial:</u> The GISC trial, conducted at conducted at Washington University in St
 Louis²¹, included 822 current or previous smokers. Genetic data were available for 796
 individuals (503 European, 257 African, 36 Other self-reported ethnicities), This dataset
 was primarily used for ancestry inference validation due to its relevance to our
 PRECISE and MOTIVATE trials.

179

<u>UKBB:</u> The UKBB dataset included 340,154 unrelated individuals with rich genetic and clinical data. This cohort consisted of 6,844 African, 730 Admixed American, 770 East Asian, 313,279 European, 7,197 South Asian, and 11,334 Other individuals by genetically-inference ancestry. The lung cancer analysis included 1,830 cases (ICD10 codes C34.0-C34.9) and 338,334 controls. The smoking cessation analysis involved 152,406 ever-smokers (117,483 former and 34,923 current), excluding 186,040 never smokers and 1,312 prefer-not-to-answer responses.

187

AoU: The AoU dataset included 210,826 unrelated individuals with whole-genome sequencing data. This cohort comprised 45,108 African, 32,563 Admixed American, 3,873 East Asian, 110,712 European, 1,689 South Asian, and 16,881 Other individuals by genetically-inference ancestry. We focused on 152,916 current or previous smokers for our smoking analysis.

193

194 <u>Construction of polygenic risk scores</u>

Our trial incorporates the latest findings by utilizing recently genome-wide association study (GWAS) summary statistics for lung cancer²⁸ and difficulty quitting smoking²⁹, excluding UK Biobank samples to avoid overlapping with our validation data. While these meta-analyses predominantly consist of individuals of European ancestry, they also include a substantial proportion of non-European ancestry — about 26% for lung cancer and 21% for difficulty quitting smoking — which enhances the generalizability of the findings^{30,31}.

202

For lung cancer risk, we started with 128 published SNPs found to be predictive of 5-203 year and lifetime cumulative risk for lung cancer¹⁶. Out of these, 101 SNPs overlapped 204 205 with the published summary statistics, reference, and validation data (1000G, UKBB, 206 GISC and AoU), and the 23andMe genotyping array used for the trial (Supplementary 207 Figure 1). These SNPs were assigned effect sizes from the fixed-effect meta-analyses estimates in the latest lung cancer GWAS that includes EUR, AFR, and EAS ancestry²⁸. 208 209 For difficulty guitting smoking, we identified 175 SNPs predictive for smoking cessation following the same filtering procedure for lung cancer²⁹. 210

211

The PRS construction began with the alignment of genotype data to the summary statistics, ensuring consistent PRS regardless of allele coding. Specifically, for any SNP *G* with reversed alleles, we recoded it as 2 - G to avoid discrepancies. The raw PRS for an individual *i* with *M* SNPs was computed as

 $PRS_i = \beta_1 G_{i1} + \beta_2 G_{i2} + \dots + \beta_M G_{iM}.$

PRS calculations were performed using R, with genotype data input via the genio
 package³². PRS SNPs and weights for lung cancer and difficulty quitting smoking are
 provided in **Supplementary Tables 2-3**, respectively.

219

220 Standardizing PRS distributions across the continuum of genetic ancestry

We standardized the PRS distributions for lung cancer and difficulty quitting smoking using the 1000G dataset, employing a regression-based method to adjust for distributional differences across ancestries (**Supplementary Tables 4-5**)²⁰. This adjustment process involves two key steps:

- 1. <u>Mean adjustment</u>: we conducted a linear regression of the raw PRS against the top
- five PCs derived from the PCA:

227
$$PRS_i = \alpha_0 + \alpha_1 PC_{i1} + \alpha_2 PC_{i2} + \dots + \alpha_5 PC_{i5} + \epsilon_i^{mean}.$$

We then computed residuals r_i of the raw PRS that account for mean differences in

229 PRS distributions across ancestry:

$$r_i = PRS_i - \widehat{\alpha_0} - \widehat{\alpha_1}PC_{i1} - \dots - \widehat{\alpha_5}PC_{i5}.$$

230 2. <u>Variance adjustment</u>: using the square residuals r_i^2 as a proxy for PRS variance, we

ran a secondary linear regression:

232
$$r_i^2 = \gamma_0 + \gamma_1 P C_{i1} + \gamma_2 P C_{i2} + \dots + \gamma_5 P C_{i5} + \epsilon_i^{var}$$

- 233
- The final ancestry-adjusted PRS for each individual *i* was then computed as:

$$PRS_i^{adj} = \frac{PRS_i - \widehat{\alpha_0} - \widehat{\alpha_1}PC_{i1} - \dots - \widehat{\alpha_5}PC_{i5}}{\sqrt{\widehat{\gamma_0} + \widehat{\gamma_1}PC_{i1} + \widehat{\gamma_2}PC_{i2} + \dots + \widehat{\gamma_5}PC_{i5}}}$$

This standardization resulted in a PRS distribution with mean 0 and variance 1 across ancestries, ensuring that genetic risk is accurately reflected independent of ancestry. This method is crucial for individuals with admixed or unknown ancestry, where discrete ancestry-specific models are inappropriate^{33,34}.

239

240 Definition of patient risk categories

We stratified patients by genetic risk for lung cancer and difficulty quitting smoking by calculating odds ratios (ORs). ORs compare the probability of an outcome occurring in

individuals within a percentile range p (i.e. 80-100%) of the ancestry-adjusted PRS distribution to those within a lower percentile range q (i.e. 0-20%).

$$OR_{pq} = \frac{P(Y = 1 | PRS \in p) / P(Y = 0 | PRS \in p)}{P(Y = 1 | PRS \in q) / P(Y = 0 | PRS \in q)}$$

245 We established cut points in the PRS distribution to categorize individuals into three risk groups: "at risk", "high risk", and "very high risk". For lung cancer, we defined these 246 247 categories as the bottom 20%, middle 60%, and top 20% of the PRS distribution. For 248 difficulty quitting smoking, categories were the bottom, middle, and top 33%. These 249 thresholds were chosen to communicate personalized risks and benefits to high-risk 250 patients in our trials, all of whom are eligible for lung cancer screening due to heavy 251 smoking. Since difficulty guitting smoking lacks established absolute risk rates, we used 252 these percentiles to provide a more agnostic risk assessment.

253

We use the distribution of our ancestry-adjusted PRSs among all 1000G samples to set percentile ranges and evaluate corresponding odds ratios among UKBB and AoU participants. For comparison, we also evaluate odds ratios using ancestry-matched raw PRS distributions, i.e. European-only 1000G PRS distribution for UKBB and AoU participants with genetically predicted European ancestry. For individual with "Other" predicted ancestry, we use the overall raw PRS distribution among all 1000G samples.

260

261 **Results**

262 Harmonization PRS distributions across ancestry

263 We found notable variation in raw PRS distributions across ancestries, highlighting that 264 applying a universal cutoff for raw PRS without accounting for ancestry can lead to 265 biased risk profiling and inaccurate clinical recommendations (Figure 4). However, our 266 regression-based ancestry adjustment across all three datasets yields much more 267 standardized distributions across ancestries. Specifically, the adjusted proportions of 268 individuals within each risk category closely align with 20%-60%-20% for lung cancer, 269 and 33.3%-33.3%-33.3% for difficulty guitting smoking. This adjustment ensures that 270 patients of any background can be compared against a unified reference distribution for 271 each outcome (Supplementary Tables 6a-f). This standardization places individuals

across all ancestries on the same scale, allowing for a single risk stratification cutoff
regardless of ancestral background. Such measures importantly enable fair risk
assessment for individuals who may be labelled as "Other", who may not fit well into a
binned ancestry-specific risk model.

276

277 Risk stratification for lung cancer and smoking cessation in UK Biobank and All of Us

278 After assigning UKB and AoU participants as "at risk", "high risk", or "very high risk" for 279 lung cancer and difficulty quitting smoking, we identified significant odds ratios for both 280 traits across different ancestry groups (Figure 5, Supplementary Tables 7-10). Our 281 ancestry-adjusted PRS yielded similar ORs as using ancestry-matched distributions, 282 demonstrating that a single PRS distribution can be appropriately applied to all 283 individuals. In UKBB, the overall ORs for lung cancer 1.42 (95% CI: 1.24 – 1.65) for the 284 "high risk" group and 1.85 (95% CI: 1.58 – 2.18) for "very high risk" group compared to 285 the "at risk" group (**Supplementary Table 7a**). In AoU, these ORs were slightly higher – 286 1.65 (95% CI: 1.36 – 2.02) for "high risk" group and 2.39 (95% CI: 1.93 – 2.97) for "very 287 high risk" group. While the ORs in non-European ancestries within UKBB were not 288 significant, they were significant and even higher than those for European ancestries in 289 AoU (Supplementary Table 8a). Moreover, the ORs for "Other" ancestry group in AoU 290 were much higher and more significant using the ancestry-adjusted PRS compared to 291 raw PRS, where an ancestry-matched risk distribution is least suitable (**Supplementary** 292 Table 8b).

293

294 We observed similar patterns for difficulty quitting smoking, where the ancestry-adjusted 295 PRS performed similar or better than using ancestry-matched distributions for raw PRS. 296 In UKBB, the overall ORs for difficulty guitting smoking were 1.19 (95% CI: 1.15 – 1.22) 297 for "high risk" group and 1.36 (95% CI: 1.32 - 1.41) for "very high risk" group 298 (Supplementary Table 9a). In AoU, the ORs were 1.12 (95% CI: 1.08 – 1.15) for "high 299 risk" group and 1.32 (95% CI: 1.28 – 1.36) for "very high risk" (Supplementary Table 300 **10a)** group. Notably, we observed higher and more significant ORs in non-European 301 AoU participants when using the ancestry-adjusted PRS compared to the raw PRS. 302 Although the improvement within each specific ancestry group was not as substantial.

the aggregate ORs in all non-European groups increased from 0.89 (95% CI: 0.86 - 0.93) to 1.05 (95% CI: 1.01 - 1.09) in the "high risk" group, and from 1.07 (95% CI: 1.03 - 1.11) to 1.23 (95% CI: 1.18 - 1.28) in the "very high risk" group.

306

Using ancestry-adjusted PRS ensures accurate risk stratification across all ethnic backgrounds, a critical consideration given the substantial variability in raw PRS distributions across diverse populations. The outcome-based validation in UKBB and AoU further verifies that the ancestry-adjusted PRS provides valid risk stratification, and often yields better risk stratification for non-European ancestries compared to ancestrymatched modeling. These findings collectively facilitate a more robust and standardized application of PRS in clinical reporting.

314

315 <u>Translating polygenic risk scores into clinical reports</u>

We highlight two example trials: PRECISE (NIDA Grant 5R01CA268030-02) and 316 MOTIVATE (NIDA Grant 5R01DA056050-02), designed to promote health behavior 317 318 change using genetically-informed interventions, RiskProfile and PrecisionTx, 319 respectively. These interventions incorporate PRS to communicate precision risk of lung cancer and precision benefits of smoking cessation, promoting evidence-based 320 321 practices such as cancer screening and tobacco treatment in high-risk individuals who 322 smoke and/or are eligible for lung cancer screening. PRS risk stratification from either 323 RiskProfile or PrecisionTx, along with clinical information, is delivered within a 324 comprehensive report that includes actionable recommendations to reduce lifetime risk 325 (Figure 6 and Figure 7). Access to 23 and Me genotypes and expanded health 326 information has been a motivating component for the research participants. Both 327 PRECISE and MOTIVATE are currently in the preliminary phases of recruiting primary 328 care providers and patients. The recruitment strategy aims to engage over 100 329 physicians and 1600 patients in these trials.

330

331 Discussion

In this study, we introduce the GREAT framework in primary care, applying PRSs in two trials to provide precise risk estimates for lung cancer and difficulty quitting smoking to

high-risk individuals. These estimates aim to activate behavior change mechanisms that promote health. To enable the interventions, we present a translational roadmap to implement genetic data in PRS-enabled interventions designed to promote health behaviors, evaluating their effectiveness in motivating high-risk patients to increase cancer screening and smoking cessation.

339

Importantly, we have accomplished our goals of generating behavior-change interventions by a) framing our translational message specifically for high-risk patients who have not received guideline-recommended cancer screening or tobacco treatment^{35–38}, b) translating risk categories into precision risk and benefit that are designed to motivate health behavior changes, and c) ensuring inclusion of diverse ancestry with PC-regression-based PRS adjustment.

346

Our goal is to enable a robust implementation of PRS in currently funded clinical trials to evaluate the efficacy of these relatively novel interventions. The GREAT framework guides the implementation of PRS-enabled interventions in primary care. Future research need to address critical questions such as timing, methodology, and location of these interventions' delivery to patients and providers to optimize its acceptability, understanding, and impact.

353

354 Our approach to ancestry adjustment of PRS employs widely accessible data from the 1000G dataset, as an alternative to methods in the GenoVA¹² and eMERGE¹¹ studies 355 356 that use data from the Mass-General Brigham Biobank and AoU, respectively. We 357 validated the transferability of our 1000G-based standardization in external datasets 358 from the UKBB, GISC and AoU, allowing future trials to adopt a similar methodology 359 irrespective of their specific genetic data. By utilizing our provided PC loadings and PRS 360 standardization formula for lung cancer and difficulty guitting smoking, new patients in 361 these trials can receive accurate risk categorization reports, bypassing the inaccuracies 362 of self-reported ethnicity and the need for re-training PCA models.

363

364 A notable gap in current practice is the absence of genetic information in electronic 365 health records (EHRs) for decision support and the lack of PRS generation in clinical 366 labs. Implementing precision interventions in primary care necessitates a workflow that 367 incorporates EHRs for recruitment, biomarker testing protocols, and standardized processes to generate personalized intervention reports³⁹. This requires collaborations 368 369 with primary care stakeholders, community advisory boards, genetic counseling, and health communication to improve intervention clarity, accuracy, and impact^{40–44}. Patients 370 371 expressed a notable interest in receiving personalized interventions. In our previous 372 study, 85% of smoking patients reported a high interest in receiving genetically tailored tobacco treatment⁴⁵. Further, a substantial majority (95%) of individuals who smoke 373 374 endorsed the importance of receiving genetic results to guide their treatment⁴¹. 375 Following receipt of a personalized genetic risk profile for smoking cessation, 91% of 376 participants who smoke found the tool highly useful for understanding their health, cope with health risks, and feeling more in control of their health⁴². Such pronounced interest 377 378 and the perceived significance of genetic data highlight the growing demand for 379 personalized interventions among patients who smoke. Personalized interventions may 380 increase patient compliance. For example, study found that patients reported higher interest in taking medication (97.5% vs. 61.0%, p<.0001) when medication was 381 personalized based on their genetics⁴⁵. However, substantial evidence suggests the 382 383 complex interplay of fear, fatalism, and risk perception when patients face lung cancer screening⁴⁶⁻⁴⁹ Therefore, it is important to evaluate the translation potential of 384 385 personalized genetics in motivating patients for positive behavior change.

386

Unlike most current research that evaluates PRS-enabled interventions in general patient populations, our work uniquely focuses on designing and evaluating these interventions specifically among high-risk patients who will benefit tremendously from recommended health behaviors such as lung cancer screening and smoking cessation, when general medical advice is not enough to motivate such behaviors.

392

393 Here we share three key design considerations for best practices. First, for equitable 394 <u>implementation</u> of precision health interventions, tools must be designed with active

engagement from racial/ethnic minority communities, rather than solely examining their effectiveness for these communities post hoc. We engage in ongoing participatory sessions with racial and ethnic minority communities and advisory boards across all phases through iterative cycles of intervention development, feedback, and testing so that innovative genomics-informed tools are beneficial across diverse populations.

400

401 Second, we have chosen clinically meaningful thresholding for PRS risk categories in 402 communicating personalized risks and benefits to patients. These categories were 403 selected because all participants in our ongoing trials are high-risk primary care patients 404 eligible for lung cancer screening, who are current or former heavy smokers. We 405 defined lung cancer risk by the bottom 20%, middle 60% and top 20%, and difficulty quitting smoking by slightly more agnostic tertiles, to motivate positive behavior change. 406 407 We aim to follow best practices of communicating uncertainties and deciding between a continuous or categorical risk presentation. Transparency about the imprecision in both 408 409 risk estimates and action thresholds for PRS is essential.

410

411 Third, we plan to update our workflow to adapt to new GWAS findings and evolving 412 methodologies. As scientific knowledge advances, outdated PRS predictions can hinder 413 effective implementation. A dynamic PRS framework that allows for regular updates 414 based on new discoveries is essential. This ensures that PRS-based interventions 415 remain current and aligned with the latest advancements, reducing the implementation 416 gap and maximizing their impact on preventive healthcare outcomes. Following current genetic counseling recommendations, we have established a process to incorporate 417 418 new evidence into our intervention for smoking cessation and lung cancer risk. This 419 process will adjudicating new population-specific evidence on genetics and biomarkers, 420 evaluating its impact on personal and population-level risk changes, and effectively 421 communicating the dynamic nature of genetic evidence to patients and providers.

422

Our work have several limitations, but we hope contribute to the knowledge pool for the
best practices in creating PRS-enabled interventions that may be disease-, population-,
or context-specific. Our approach is tailored for our unique outcomes (lung cancer and

426 difficulty guitting smoking), population (patients eligible for lung cancer screening and 427 tobacco treatment), and context (primary care) to optimize health impact. A notable 428 limitation is the underrepresentation of non-European populations in the multi-ancestry 429 GWAS employed to derive the PRS weights. This underrepresentation may reduce the 430 predictive power of the PRS in non-European populations. The dominance of European populations persists in existing GWAS⁵⁰⁻⁵³, not limited to lung cancer and smoking 431 432 cessation. However, with the burgeoning emphasis on incorporating minority populations in GWAS analyses and the development of new PRS approaches and 433 toolkits to enhance predictive power in diverse populations $^{7-9,34,54-56}$, we can iteratively 434 refine PRS implementation in our trial to synchronize with the latest advancements. 435

436

Many questions remain for the near future. First, how can we reduce the time lag from 437 438 evidence to implementation? The constant evolution of evidence identifying new 439 biomarkers for treatment is a challenge. For instance, our recent work highlights the potential of PRSs in guiding future treatment approaches⁵⁷. Despite actionable precision 440 treatment findings, the ever-changing evidence base and the perception of better data 441 have hindered effective implementation^{43,58}. To address this, we aim to use cutting-edge 442 metabolic and genetic markers that offer robust evidence for precision treatment, 443 444 reducing the time from evidence generation to practical application. This approach 445 allows us to measure and report the time from landmark publications to the implementation of key findings 59, enhancing the efficiency and effectiveness of 446 447 precision treatment and ensuring patients benefit from the latest recommendations.

448

449 Second, can we truly evaluate the effect of precision interventions? We expect that 450 precision interventions may activate multiple mechanistic pathways to the uptake and 451 efficacy of lung cancer screening or tobacco treatment. Understanding these mechanisms is essential to refine for intended outcomes and contexts. Third, can these 452 453 precision interventions be scaled in the real-world clinics? Evidence shows that physicians are highly receptive to medication recommendations based on biomarkers⁶⁰. 454 455 To reduce burden, we need to leverage existing EHR tools (e.g. Best Practice Advisories) and training to efficiently facilitate physician prescribing^{61,62}. Understanding 456

of mechanistic and implementation outcomes will guide scalable, efficient delivery
 components for integration into clinic workflows³⁹, using trained embedded staff, and
 digital therapeutic tools to enable these PRS-informed behavioral interventions⁶³.

460

461 In conclusion, a well-designed roadmap that validates the PRS, incorporates multi-462 GWAS-based weights. translates actionable ancestry risk into categories. 463 communicates effectively, considers patient perspectives, and accommodates evolving science is essential for the equitable and pragmatic translation of PRS into clinical care. 464 By addressing the barriers and implementing potential solutions at each stage, we can 465 leverage PRS to improve preventive healthcare and significantly reduce the burden of 466 467 lung cancer.

468 Acknowledgements

We would like to thank Reeya Joseph for her editorial support with the introduction, Peter Kraft for his advice on our manuscript, and Scott Vrieze for his assistance with summary statistics for difficulty quitting smoking. We would also like to thank and acknowledge the participants enrolled in the UK Biobank (obtained under UK Biobank resource application 52008) and GISC trial for contributing vital data to this work.

474

This research was supported by NIH Training Grant T32GM135117 and NSF Graduate
Research Fellowship DGE-2140743 (T.C.), R35-3CA197449, R01-HL163560, U01HG009088, and U01-HG012064 (X.L.), NIH Intramural Research Program (H.Z.), NIH
5T32-HL007776-25, R01-DA056050, R01-CA268030, P30-CA091842-19S5, P30CA091842-16S2 and P50-CA244431 (L.C.) and U19-CA203654.

480

481 Author Contributions

T.C., H.Z., and L.C. conceived the project, T.C., G.P., and L.F. carried out all data
analyses under the supervision of H.Z. and L.C. G.S. and D.J. assisted with obtaining
and processing GWAS summary statistics for difficulty quitting smoking. T.C., G.P., H.Z.,
and L.C. drafted the manuscript. All co-authors reviewed and approved the final version
of the manuscript.

487

488 **Conflicts of Interest**

Laura J. Bierut is listed as an inventor on Issued U.S. Patent 8,080,371, "Markers for Addiction" covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Michael J. Bray is an employee at ThinkGenetic, Inc. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.

- 496 All other authors have no conflict of interests to report.
- 497


498 Data and Code Availability

R code and plink commands, as well as accompanying data, used for analysis are provided in a walkthrough available on GitHub at <u>https://github.com/chen-tony/GREAT</u>.

- 501
- 502 Genotype data from the 1000 Genomes Project (Phase 3) were acquired via the plink
- 503 website <u>https://www.cog-genomics.org/plink/2.0/resources</u>. Population information were
- 504 obtained from public resources:
- 505 <u>ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/</u> and
- 506 <u>https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000G_2504_high_coverag</u>
- 507 <u>e/1000G_698_related_high_coverage.sequence.index</u>.


508 Figures

509




Mechanisms for health behavior change

Figure 1. Care Paradigm: Genomic Informed Care for Motivating High Risk 510 Individuals Eligible for Evidence-based Prevention (GREAT). The GREAT 511 512 framework is a primary care paradigm that integrates genetic and clinical risk in 513 precision health. Individuals and their providers in two upcoming trials (PRECISE and 514 MOTIVATE) are enrolled and provided with multilevel interventions (e.g. RiskProfile and PrecisionTx) to promote clinical outcomes of lung cancer screening, tobacco treatment, 515 516 and successful smoking cessation in primary care settings. Mechanisms of health 517 behavior changes (e.g., perceived benefit, self-efficacy, and outcome expectancy) will be evaluated. During the specific actionable recommendations phase, personalized 518 519 shared decision-making will be facilitated by multilevel actions between patients and 520 clinicians for better clinical outcomes.



523

524 Figure 2 Roadmap for translating genetic data to a genetic risk profile as a multilevel intervention in primary care. In step 1, enrolled participants' genetic data 525 are analyzed by 23andMe's Clinical Laboratory Improvement Amendments (CLIA) 526 527 certified genotyping process. Imputation and guality controls are conducted through the 528 Trans-Omics for Precision Medicine (TOPMed) server to ensure the integrity and reliability of the genetic data, as well as to impute the GWAS variants. Step 2 involves 529 identifying available GWAS variants and weights to create the raw Polygenic Risk 530 531 Scores (PRS). The PRS is adjusted for genetic ancestry using reference data such as 532 the 1000 Genomes Project Phase 3 and applied to validation data such as the UK 533 Biobank to establish risk categories and compute ORs. In step 3, these scores are converted into 3 risk levels based on the established thresholds. In step 4, a report with 534 precision treatment is created and communicated to both the participant and the 535 536 provider to make informed and educated decisions. Behavioral interventionists 537 (research staff who are trained, certified, and supervised by a team of genetic counselor, psychologist, and psychiatrist) offer personalized guidance on behavior change, 538 539 leveraging the updated genetic insights. The outcome aims to increase lung cancer screening orders, improve participant adherence, promote smoking cessation, and 540 541 highlight the benefits of tobacco treatment.




542

• AFR • AMR • EAS • EUR • SAS • Other

Figure 3. Cross-dataset distribution of genetic ancestry via PCA Projections in 1000G, GISC, UKBB, and AoU. This figure illustrates the utility of principal components analysis (PCA) loadings obtained from the 1000 Genomes Project Phase 3 (1000G) in discriminating ancestries within external datasets, the Genetically Informed Smoking Cessation (GISC) trial. PCA was initially conducted on the globally diverse genotype data of 1000G. The resultant PCA-space was then used to project genotype data from GISC, UKBB, and AoU. The scatter plot displays the first and second PCs for each


550 individual in these datasets, with points distinctly marked by genetically-inferred

551 ancestry.




552

Figure 4 Ancestry adjustment of PRS for lung cancer and guit difficulty PRS 553 across ancestral populations. We showcase the adjustment process for polygenic 554 risk scores (PRS) for lung cancer (Panel A) and difficulty quitting smoking (Panel B) 555 within the 1000 Genomes Project (1000G), GISC Trial, UK Biobank, and All of Us 556 datasets. It displays both raw and ancestry-adjusted PRS, with data points color-coded 557 according to genetically-inferred ancestries. EAS, AMR, and SAS ancestries were 558 559 removed for GISC due to their small sample sizes. Ancestry adjustment effectively 560 centers the PRS for different ancestries, mitigating the risk of incorrect stratification due to ancestry-related biases. Dotted vertical lines correspond to the 20th and 80th 561 percentiles for lung cancer PRS distribution and 33rd and 67th percentiles for difficulty 562 quitting smoking PRS among all 3,202 samples in the 1000 Genomes Project. 563



565

Figure 5. Risk stratification for lung cancer and difficulty quitting smoking using raw and ancestry-adjusted PRS. This figure illustrates the odds ratios (ORs) with associated 95% confidence intervals of PRSs for lung cancer (A) and difficulty quitting smoking (B) among UK Biobank (N=340,154 for lung cancer and N=152,406 for smoking), and All of Us (N=210,826 for lung cancer and N=152,916 for smoking) participants. We compare risk stratification using a raw PRS with ancestry-matched percentiles, and our ancestry-adjusted PRS with the same percentiles for all individuals.



573

Figure 6. Example 1 clinical report: RiskProfile. We present example 1 for 574 575 genomically-informed interventions using the GREAT framework. RiskProfile is 576 designed to motivate lung cancer screening and tobacco treatment among screeningeligible patients. This intervention utilizes ancestry-adjusted PRS to stratify patients into 577 "at risk" (yellow), "high risk" (orange), and "very high risk" (red) genetic risk categories. 578 RiskProfile focuses on prevention and expands beyond personalized risk to also provide 579 personalized benefit of cancer screening and use a multilevel intervention design 580 directed to both physicians and patients in clinical settings. In an ongoing NCI-funded 581 trial (NCT05627674), the effect of RiskProfile on clinician ordering and patient completion of 582 lung cancer screening will be evaluated. 583






Figure 7. Example 2 clinical report: PrecisionTx. We present example 2 for 585 586 genomically-informed interventions using the GREAT framework. PrecisionTx is designed to motivate tobacco treatment among patients who smoke. This intervention 587 utilizes ancestry-adjusted PRS to stratify patients into "at risk" (yellow), "high risk" 588 589 (orange), and "very high risk" (red) genetic risk categories. PrecisionTx focuses on treatment and expands beyond personalized risk to also provide personalized benefit of 590 tobacco treatment, and use a multilevel intervention design directed to both physicians 591 and patients in clinical settings. In an ongoing NIDA-funded trial (NCT05846841), the 592 effect of PrecisionTx on clinician ordering, patient adherence, and smoking abstinence 593 594 will be evaluated.

595 Tables

| | GenoVA | eMERGE | Wisdom | PRECISE / MOTIVATE |
|------------------------------|--|--|---|---|
| Goal | Motivate early diagnosis | Increasing clinical actions to mitigate risk of future disease | Personalized screening frequency | Motivate lung cancer screening (LCS) / tobacco treatment |
| Targets | | | | |
| Target population | All general Veterans' Affairs PCP* and patients | Patients in the large healthcare system | All women can sign up online | High risk PC patients (LCS eligible / smokers) and their PCPs |
| Condition(s)** | BrCa, PrCa, CRCa, Afib, CAD, T2D | BrCa, PrCa, CRCa, Afib, CAD, T1D, T2D, BMI, Asthma, CKD, HCL | BrCA | LC, smoking cessation |
| Target outcome | New diagnoses | Change screening practice or lifestyle | Screening compliance and cancer detection | LCS, tobacco tx, and smoking cessation |
| Polygenic Risk Scores | | | | |
| Genotyping | Study team | | Color genomics | 23andMe |
| Imputation | 1000 Genomes | All of Us | | TOPMed |
| Create PRS | Top or many variants European weights Ancestry calibration | Terra cloud platform Ancestry calibration | Color genomics | Top independent variants Multi-ancestry weights Ancestry calibration |
| Risk Stratification | 2 levels (OR of 2) | OR of 5-10 | | 3 levels (top 20%, middle, bottom 20%) or tertiles |
| Intervention Design | | | | |
| Risk representation | Only genetic Format of relative risk | Combined clinical + genetic Format of absolute risk | Combined clinical + genetic Format of absolute risk | Separate genetic + clinical Format of relative risk |
| Messaging | Average vs. elevated risk | Average vs. elevated risk | No discussion of risk Only recommend screening schedule | At risk, at high risk, or at very high risk |
| Behavior mechanisms targeted | | | | Perceived risk/benefit, Self efficacy, Personal relevance |

596

597 * PCP=primary care provider

** BrCa=breast cancer, PrCa=prostate cancer, CRCa=colorectal cancer, Afib=atrial
 fibrillation, CAD=coronary artery/heart disease, T2D=type 2 diabetes, T1D=type 1
 diabetes, BMI=body mass index/obesity, CKD=chronic kidney disease,
 HCL=hypercholesterolemia, lung cancer=lung cancer

602

603 Table 1. Research on PRS use in clinical trials. We compare the PRECISE and 604 MOTIVATE trials, part of our GREAT framework, with existing PRS-informed trials: 605 GenoVA, eMERGE, and WISDOM. Bolded text in the PRECISE / MOTIVATE column 606 highlight the points where our trials differ from the current trials. Namely, the PRECISE 607 and MOTIVATE trials investigate lung cancer and smoking and will focus on high risk 608 patients who are smokers or eligible for lung cancer screening. We also look at lung 609 cancer screening, tobacco treatment, and smoking cessation as unique target outcomes. 610 Finally, in addition to genetic and clinical risk messaging, the two trials have a unique 611 emphasis on behavior mechanisms around lung cancer and smoking.

613 **References**

- Kocarnik, J. M. *et al.* Cancer Incidence, Mortality, Years of Life Lost, Years Lived With
 Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019.
 JAMA Oncol 8, 420 (2022).
- 617 Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic 2. 618 risk scores. Nature Reviews Genetics vol. 19 581-590 Preprint at 619 https://doi.org/10.1038/s41576-018-0018-x (2018).
- 620 3. Lewis, C. M. & Vassos, E. Polygenic risk scores: From research tools to clinical instruments.
 621 *Genome Medicine* vol. 12 Preprint at https://doi.org/10.1186/s13073-020-00742-5
 622 (2020).
- 623 Adeyemo, A. et al. Responsible use of polygenic risk scores in the clinic: potential benefits, 4. 624 risks and gaps. Nature Medicine vol. 27 1876-1884 Preprint at 625 https://doi.org/10.1038/s41591-021-01549-6 (2021).
- 5. Vilhjálmsson, B. J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of Polygenic
 Risk Scores. *Am J Hum Genet* **97**, 576–592 (2015).
- 628 6. Wray, N. R., Goddard, M. E. & Visscher, P. M. Prediction of individual genetic risk to 629 disease from genome-wide association studies. *Genome Res* **17**, 1520–1528 (2007).
- 630 7. Zhang, H. *et al.* A new method for multiancestry polygenic prediction improves
 631 performance across diverse populations. *Nat Genet* (2023) doi:10.1038/s41588-023632 01501-z.
- 8. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* 54, 573–580 (2022).
- 635 9. Chen, T., Zhang, H., Mazumder, R. & Lin, X. Ensembled best subset selection using
 636 summary statistics for polygenic risk prediction. *bioRxiv* (2023)
 637 doi:10.1101/2023.09.25.559307.
- Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health
 disparities. *Nat Genet* 51, 584–591 (2019).
- 64011.Linder, J. E. *et al.* Returning integrated genomic risk and clinical recommendations: The641eMERGE study. *Genetics in Medicine* **25**, 100006 (2023).
- Hao, L. *et al.* Development of a clinical polygenic risk score assay and reporting workflow. *Nat Med* 28, 1006–1013 (2022).
- 64413.Shieh, Y. et al. Breast Cancer Screening in the Precision Medicine Era: Risk-Based645Screening in a Population-Based Trial. J Natl Cancer Inst 109, djw290 (2017).
- 64614.Zhang, P. et al. Association of smoking and polygenic risk with the incidence of lung647cancer: a prospective cohort study. Br J Cancer 126, 1637–1646 (2022).
- 648 15. Kanwal, M., Ding, X.-J. & Cao, Y. Familial risk for lung cancer. *Oncol Lett* **13**, 535–542 (2017).
- Hung, R. J. *et al.* Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk
 Model. *Cancer Res* 81, 1607–1615 (2021).
- Michie, S. Making psychological theory useful for implementing evidence based practice:
 a consensus approach. *Qual Saf Health Care* 14, 26–33 (2005).
- 18. Cane, J., O'Connor, D. & Michie, S. Validation of the theoretical domains framework for
 use in behaviour change and implementation research. *Implementation Science* 7, 37
 (2012).

657 19. Atkins, L. et al. A guide to using the Theoretical Domains Framework of behaviour change 658 to investigate implementation problems. Implementation Science 12, 77 (2017). 659 20. Ge, T. *et al.* Development and validation of a trans-ancestry polygenic risk score for type 2 660 diabetes in diverse populations. *Genome Med* **14**, 70 (2022). 661 Chen, L. et al. Genetic Variant in CHRNA5 and Response to Varenicline and Combination 21. 662 Nicotine Replacement in a Randomized Placebo-Controlled Trial. Clin Pharmacol Ther 108, 663 1315-1325 (2020). 664 Sudlow, C. et al. UK Biobank: An Open Access Resource for Identifying the Causes of a 22. 665 Wide Range of Complex Diseases of Middle and Old Age. *PLoS Med* **12**, e1001779 (2015). 666 Bick, A. G. et al. Genomic data in the All of Us Research Program. Nature (2024) 23. 667 doi:10.1038/s41586-023-06957-x. 668 24. Auton, A. et al. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015). 669 25. Byrska-Bishop, M. *et al.* High-coverage whole-genome sequencing of the expanded 1000 670 Genomes Project cohort including 602 trios. Cell 185, 3426-3440.e19 (2022). 671 26. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer 672 datasets. Gigascience 4, 7 (2015). 673 Chen, S. et al. A genome-wide mutational constraint map quantified from variation in 27. 674 76,156 human genomes. bioRxiv 2022.03.20.485034 (2022)675 doi:10.1101/2022.03.20.485034. 676 28. Byun, J. et al. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 677 controls identifies new susceptibility loci contributing to lung cancer. Nat Genet 54, 678 1167-1177 (2022). 679 29. Saunders, G. R. B. et al. Genetic diversity fuels gene discovery for tobacco and alcohol use. 680 Nature 612, 720-724 (2022). 681 30. Martin, A. R. et al. Human Demographic History Impacts Genetic Risk Prediction across 682 Diverse Populations. The American Journal of Human Genetics 100, 635–649 (2017). Manrai, A. K. et al. Genetic Misdiagnoses and the Potential for Health Disparities. New 683 31. 684 England Journal of Medicine **375**, 655–665 (2016). 685 32. Ochoa, A. genio: Genetics Input/Output Functions. Preprint at https://CRAN.R-686 project.org/package=genio (2023). 687 Lewis, A. C. F. et al. Getting genetic ancestry right for science and society. Science (1979) 33. 688 **376**, 250–252 (2022). 689 Kachuri, L. et al. Principles and methods for transferring polygenic risk scores across 34. 690 global populations. Nat Rev Genet (2023) doi:10.1038/s41576-023-00637-2. 691 35. US Preventive Services Task Force. Lung Cancer: Screening. 692 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-693 screening (2021). 694 36. Agency for Healthcare Research and Quality. Clinical Guidelines and Recommendations. 695 https://www.ahrq.gov/prevention/guidelines/index.html (2021). 696 Tobacco Use and Dependence Guideline Panel. US Department of Health and Human 37. 697 Services. (2008). Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and 698 Dependence: 2008 Update. (US Department of Health and Human Services, Rockville, MD, 699 2008). 700 Krist, A. H. et al. Screening for Lung Cancer. JAMA 325, 962 (2021). 38.

39. Ayatollahi, H., Hosseini, S. F. & Hemmat, M. Integrating Genetic Data into Electronic
Health Records: Medical Geneticists' Perspectives. *Healthc Inform Res* 25, 289 (2019).

- 40. Bourdon, J. L. *et al.* In-vivo design feedback and perceived utility of a genetically-informed
 smoking risk tool among current smokers in the community. *BMC Med Genomics* 14, 139
 (2021).
- 70641.Ramsey, A. T. et al. Participatory Design of a Personalized Genetic Risk Tool to Promote707Behavioral Health. Cancer Prevention Research 13, 583–592 (2020).
- Ramsey, A. T. *et al.* Proof of Concept of a Personalized Genetic Risk Tool to Promote
 Smoking Cessation: High Acceptability and Reduced Cigarette Smoking. *Cancer Prevention Research* 14, 253–262 (2021).
- 71143.Ramsey, A. T. *et al.* Toward the implementation of genomic applications for smoking712cessation and smoking-related diseases. *Transl Behav Med* 8, 7–17 (2018).
- 713 44. Chen, L.-S., Baker, T. B., Ramsey, A., Amos, C. I. & Bierut, L. J. Genomic medicine to reduce
 714 tobacco and related disorders: Translation to precision prevention and treatment.
 715 Addiction Neuroscience 7, 100083 (2023).
- 71645.Chiu, A. *et al.* Most Current Smokers Desire Genetic Susceptibility Testing and Genetically-717Efficacious Medication. Journal of Neuroimmune Pharmacology 13, 430–437 (2018).
- 46. Quaife, S. L., Janes, S. M. & Brain, K. E. The person behind the nodule: a narrative review
 of the psychological impact of lung cancer screening. *Transl Lung Cancer Res* 10, 2427–
 2440 (2021).
- 47. Quaife, S. L. *et al.* Psychological Targets for Lung Cancer Screening Uptake: A Prospective
 Longitudinal Cohort Study. *Journal of Thoracic Oncology* 16, 2016–2028 (2021).
- 48. Quaife, S. L., Marlow, L. A. V., McEwen, A., Janes, S. M. & Wardle, J. Attitudes towards
 lung cancer screening in socioeconomically deprived and heavy smoking communities:
 informing screening communication. *Health Expectations* 20, 563–573 (2017).
- 49. Quaife, S. L., McEwen, A., Janes, S. M. & Wardle, J. Smoking is associated with pessimistic
 and avoidant beliefs about cancer: results from the International Cancer Benchmarking
 Partnership. *Br J Cancer* 112, 1799–1804 (2015).
- 729 50. Peterson, R. E. *et al.* Genome-wide Association Studies in Ancestrally Diverse Populations:
 730 Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**, 589–603 (2019).
- 731
 51.
 Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. Nature 538, 161–164

 732
 (2016).
- 733 52. Need, A. C. & Goldstein, D. B. Next generation disparities in human genomics: concerns
 734 and remedies. *Trends in Genetics* 25, 489–494 (2009).
- Fitipaldi, H. & Franks, P. W. Ethnic, gender and other sociodemographic biases in genomewide association studies for the most burdensome non-communicable diseases: 2005–
 2022. *Hum Mol Genet* 32, 520–532 (2023).
- 73854.Jin, J. et al. MUSSEL: Enhanced Bayesian polygenic risk prediction leveraging information739across multiple ancestry groups. Cell Genomics 4, 100539 (2024).
- 740 55. Zhang, J. *et al.* An ensemble penalized regression method for multi-ancestry polygenic
 741 risk prediction. *Nat Commun* **15**, 3238 (2024).
- For the second second

- 57. Bray, M. *et al.* The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence
 From Two Treatment Trials. *Nicotine & Tobacco Research* 24, 1573–1580 (2022).
- 74658.Ramsey, A. T. *et al.* Designing for Accelerated Translation (DART) of emerging innovations747in health. J Clin Transl Sci **3**, 53–58 (2019).
- Proctor, E. *et al.* FAST: A Framework to Assess Speed of Translation of Health Innovations
 to Practice and Policy. *Global Implementation Research and Applications* 2, 107–119
 (2022).
- 75160.Scoville, E. A. *et al.* Precision nicotine metabolism-informed care for smoking cessation in752Crohn's disease: A pilot study. *PLoS One* **15**, e0230656 (2020).
- 75361.Chen, L.-S. *et al.* Low-Burden Strategies to Promote Smoking Cessation Treatment Among754Patients With Serious Mental Illness. *Psychiatric Services* **69**, 849–851 (2018).
- 755 62. Ramsey, A. T. et al. Care-paradigm shift promoting smoking cessation treatment among 756 cancer center patients via a low-burden strategy. Electronic Health Record-Enabled 757 Evidence-Based Smoking Cessation Treatment. Transl Behav Med (2019) 758 doi:10.1093/tbm/ibz107.
- Kaphingst, K. A. *et al.* Comparing models of delivery for cancer genetics services among
 patients receiving primary care who meet criteria for genetic evaluation in two
 healthcare systems: BRIDGE randomized controlled trial. *BMC Health Serv Res* 21, 542
 (2021).
- 763
- 764